NCT03490500

Using the S100B Protein for Emergency Headache Management Care (S100)

Improving the Headache Management Care in the Emergency Unit by Using a Biological Marker: S100B Protein.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 63 (actual)
• Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the negative predictive value of protein S100B that could exclude subarachnoid and intracranial haemorrhage for patient that present severe headache within the last 3 hours.

Detailed description

This study will be proposed to every patient that correspond to eligibility criteria, such as presenting a severe headache (Visual Analog Scale ≥ 6/10) within 3 hours before arriving to the emergency. After signing the informed consent, a blood sample will be taken in order to dosage S100B protein of each patient, and then they will have a brain scan. The trial ends after the brain scan for each patient. Results of brain scans will be compared with results of S100B dosage.

Conditions

• Headache, Migraine
• Hemorrhage

Timeline

• Start date: 2018-10-24
• Primary completion: 2020-01-24
• Completion: 2020-01-24
• First posted: 2018-04-06
• Last updated: 2022-10-13

Locations

3 sites across 1 country: France